EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Re-evaluation of the cardioprotective effects of cannabinoids against ischemia-reperfusion injury according to the IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria

Anna Pędzińska-Betiuk, Eberhard Schlicker, Jolanta Weresa, Barbara Malinowska

Frontiers in Pharmacology · 30.05.2024 · 15

DOI: 10.3389/fphar.2024.1382995 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.05.2024. Verfasst von Anna Pędzińska-Betiuk und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, Bialystok, Poland. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ischemic heart disease, associated with high morbidity and mortality, represents a major challenge for the development of drug-based strategies to improve its prognosis. Results of pre-clinical studies suggest that agonists of cannabinoid CB 2 receptors and multitarget cannabidiol might be potential cardioprotective strategies against ischemia-reperfusion injury. The aim of our study was to re-evaluate the cardioprotective effects of cannabinoids against ischemia-reperfusion injury according to the IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria published recently by the European Union (EU) CARDIOPROTECTION COST ACTION. To meet the minimum criteria of those guidelines, experiments should be performed (i) on healthy small animals subjected to ischemia with reperfusion lasting for at least 2 hours and (ii) confirmed in small animals with comorbidities and co-medications and (iii) in large animals. Our analysis revealed that the publications regarding cardioprotective effects of CB 2 receptor agonists and cannabidiol did not meet all three strict steps of IMPACT. Thus, additional experiments are needed to confirm the cardioprotective activities of (endo)cannabinoids mainly on small animals with comorbidities and on large animals. Moreover, our publication underlines the significance of the IMPACT criteria for a proper planning of preclinical experiments regarding cardiac ischemia-reperfusion injury.

Schlagwörter

Stichwörter der Autor:innen

CannabidiolCannabinoid receptorCannabinoidsIMproving Preclinical assessment of Cardioprotective therapies (IMPACT)Myocardial infarctionMyocardial ischemia-reperfusion injury

Autor:innen und Institutionen

  • Department of Experimental Physiology and Pathophysiology, Medical University of Bialystok, Bialystok, Poland.
  • Department of Pharmacology and Toxicology, University of Bonn, Bonn, Germany.

Zitieren

APA

Pędzińska-Betiuk, A., Schlicker, E., Weresa, J., & Malinowska, B. (2024). Re-evaluation of the cardioprotective effects of cannabinoids against ischemia-reperfusion injury according to the IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1382995

Vancouver

Pędzińska-Betiuk A, Schlicker E, Weresa J, Malinowska B. Re-evaluation of the cardioprotective effects of cannabinoids against ischemia-reperfusion injury according to the IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1382995

BibTeX
@article{PdziskaBetiuk2024,
  author = {Pędzińska-Betiuk, Anna and Schlicker, Eberhard and Weresa, Jolanta and Malinowska, Barbara},
  title = {Re-evaluation of the cardioprotective effects of cannabinoids against ischemia-reperfusion injury according to the IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1382995}
}
Kostenlos starten →